J. Michael Pearson

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) stock surged to 12.50 percent to $109.80 in Tuesday's afternoon trading session, following its new 20-year deal announcement to cut prices for Walgreens Boots Alliance Inc (NASDAQ: WBA). The drug deal comes six weeks after the company had cut ties with...

The CEO of Valeant Pharmaceuticals released a letter this week addressing the company’s falling share price. CEO J. Michael Pearson believes that market fears over Valeant’s inability to deliver growth in a potentially harsh regulatory environment  are overblown. Pearson...

The stakeholders in the upcoming deal for Allergan (NYSE: AGN) see a perfect fit. “When you understand their operating philosophy and their approach to capital allocation discipline, cost discipline, the way they compensate their team, in fit into the Pershing mold of an investment, and that's...